Safety & Tolerability
EPS and akathisia profile was similar to placebo with CAPLYTA1,3
Incidence of extrapyramidal symptoms (EPS)* and akathisia in acute trials (4- to 6-week)1,3
- Data were collected in patients with acute schizophrenia over 4-6 weeks1,3
EPS (extrapyramidal symptoms) includes akathisia, extrapyramidal disorder, muscle spasms, restlessness, musculoskeletal stiffness, dyskinesia, dystonia, muscle twitching, tardive dyskinesia, tremor, drooling, and involuntary muscle contractions.1
In the 4- to 6-week trials, data were collected using the Simpson-Angus Scale (SAS) for EPS (total score ranges from 0 to 40), the Barnes Akathisia Rating Scale (BARS) for akathisia (total score ranges from 0 to 14), and the Abnormal Involuntary Movement Scale (AIMS) for dyskinesia (total score ranges from 0 to 28). The mean changes from baseline for CAPLYTA-treated patients and placebo-treated patients were 0.1 and 0 for the SAS, -0.1 and 0 for the BARS, and 0.1 and 0 for the AIMS, respectively.1,3
This graph depicts the incidence of extrapyramidal symptoms (EPS) and akathisia over 4-6 weeks for patients receiving CAPLYTA 42 mg or pacebo.
Patients on CAPLYTA saw a 6.7-point increase in EPS incidence, including akathisia, vs 6.3-point increase for those on placebo. Patients on CAPLYTA saw a 2.0-point increase in akathisia incidence vs 2.9-point increase for those on placebo.